Glycoprotein E (VZV) 분자 정보
Molecule Name
Envelope (E) protein
분자 별명
gE
Drug Development Progress
임상 약물 수2
시판 약물 수0
최고 연구 개발 단계Phase 1 Clinical
표적 별명
gE-1，Envelope glycoprotein E，gE
제품 문의
FAQ
What should be matched before selecting a gE assay?
Check species, assay purpose, antigen format, and whether the readout is antigen detection or antibody titer.
Does the gE kit measure viral load?
The listed kits are antibody or antigen ELISA tools; they are not described as viral-load assays.
Can VZV gE reagents support vaccine research?
Yes. Recombinant gE, antigen ELISA kits, and antibody-titer kits support distinct antigen-characterization and immune-response endpoints.
Which antibody reagents are included?
Available options include anti-gE monoclonal antibodies, including an unconjugated and a biotinylated format.
Is a biotinylated gE protein available?
GLE-V82E3 is biotinylated VZV gE with His and AviTag.
Which gE assay kits are available?
Available options include VZV gE ELISA kits and mouse or human anti-VZV IgG-titer serology kits.
Why is VZV gE relevant to antibody research?
gE is an abundant, immunogenic glycoprotein on virus and infected-cell surfaces, making it relevant to antigen-specific antibody studies.
Which VZV gE antigen is available?
The portfolio includes gE from varicella-zoster virus strain Oka vaccine, expressed as a His-tagged recombinant protein.
Asset Licensing Opportunity
Resources
임상 약물 정보
| 영어 이름 | 연구 코드 | 연구 개발 단계 | 회사 | 적응증 | 임상 시험 |
|---|---|---|---|---|---|
| LHF-535 | LHF-535; LHF-535-SDD | Phase 1 Clinical | Kineta Inc | 상세 | |
| SAR-440894 | SAR-440894 | Phase 1 Clinical | National Institute Of Allergy And Infectious Diseases (Niaid) | Chikungunya Fever | 상세 |
Customer Reviews